Strength Training Response of Muscle in GLP-1 Users
- Conditions
- Muscle Mass
- Registration Number
- NCT07104539
- Brief Summary
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 30
- Age, 50y+
- Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
- Weight <300 lb
- Pass a health and exercise readiness screening
- Age <50
- Weight >300 lb
- Osteoporosis
- Active metabolic, neoplastic, or cardiovascular disease
- Unable or unwilling to provide consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Muscle mass by d3-creatine dilution Water containing creatine isotope consumed in lab; Urine sample collection on Day 0 and Day 3 at baseline and 14 weeks. Participants will collect a urine sample prior to be provided a creatine capsule containing 30 milligrams of a naturally-occurring creatine isotope. A glass of water will be provided to wash it down. Participants will be asked to return \~3 days later to provide another urine sample. Urine samples will be analyzed at an off-site laboratory to determine changes in d3-creatine excretion before and after the 14-week strength training intervention.
Balance testing - Percentage of failed recoveries 2-hour testing session in lab at baseline and 14 weeks. Participants will stand on the treadmill with the belt stationary. The belt will then suddenly change to a speed specified by the investigator, and the participant will attempt to step to maintain their balance and establish a stable gait. In addition to the treadmill itself, this system includes an integrated fall arrest harness that is anchored to an overhead gantry that is fixed to the treadmill. This harness prevents any body part but the feet from impacting the treadmill in the event that the participant is unable to maintain their balance after a sudden change in speed.
- Secondary Outcome Measures
Name Time Method Muscle function 500-meter timed walk in lab at baseline and 14 weeks Participants will walk 500 meters down and back along a hallway at a self-selected pace. The walk will be measured, supervised, and timed by lab personnel.